Biologic Shows Promise in Ongoing Food Allergy Trial
LOUISVILLE, Ky. — Omalizumab (Xolair) may be an effective therapy for patients with multiple food allergies, according to an ongoing phase III trial. Most of the first 60 patients with multiple food allergies enrolled in stage one of the OUtMATCH clinical trial were able to tolerate serving-sized portions of those foods a year after receiving […]
Pragmatic Trials May Help Increase Minority Participation in MS Research
Pragmatic trials may offer one way to increase minority populations in multiple sclerosis (MS) studies, investigators for the DELIVER-MS trial suggested. Race and ethnicity did not appear to influence decisions to participate in either the randomized or observational cohorts of the pragmatic DELIVER-MS study, or in treatment choices, reported Sarah Planchon, PhD, of the Cleveland […]
Year in Review: Multiple Myeloma
Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging news and disappointments on the research front. New Approvals Last month, the FDA granted accelerated approval to teclistamab (Tecvayli) […]
No Excess Pregnancy, Infant Risks With Ocrelizumab for MS
Women with multiple sclerosis (MS) who were treated with ocrelizumab (Ocrevus) had no increased risk of adverse pregnancy and infant outcomes, prospective data showed. Cumulative data did not suggest an increased risk of preterm birth, major congenital anomalies, or other adverse outcomes with ocrelizumab in utero exposure and were consistent with epidemiological data, reported Celia […]
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab
Treatment options for relapsed/refractory multiple myeloma continue to expand with FDA’s accelerated approval of teclistamab (Tecvayli). The approval stipulates use of the bispecific antibody in adults who have received at least four prior therapies, including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody (triple-class refractory disease). The first approved drug of its kind, teclistamab […]
Draft Genome Sequence of Latest Monkeypox Virus Unveiled
The latest monkeypox virus now popping up in multiple countries appears most closely related to a strain that circulated in 2018-2019, according to a draft genome sequence of a recent case. Sequencing of a skin lesion sample from an infected male patient in Portugal — where at least 20 confirmed cases have been reported — […]
Good Vibrations: The Transition from Sex Toy to Medical Device
NEW ORLEANS — Formal medical studies of vibrators have revealed positive effects on multiple sexual and urinary outcomes in women, a review of published literature showed. Though limited in number, the studies induced favorable changes in blood flow and muscle tone of genital tissues, improved multiple aspects of sexual arousal and satisfaction, increased orgasmic response, […]
4D composite printing can improve the wings of drones
The aviation industry faces multiple pressures from higher fuel costs and increased scrutiny over the environmental and quality-of-life impacts from its aircraft. Researchers are looking for new methods of keeping expenses down while improving overall efficiency, and the relatively new market of unmanned aerial vehicles (UAVs) — or drones — is no exception. UAVs are […]
Deep Learning Identifies PPMS Patients Who May Respond to Treatment
Deep learning identified subgroups of patients with primary progressive multiple sclerosis (PPMS) who may respond to disease-modifying therapy, researchers said. A trained model separated responders and non-responders across a range of predicted effect sizes, reported Jean-Pierre Falet, MD, of McGill University in Montreal, Canada, at the ACTRIMS Forum 2022, the annual meeting of the Americas […]
Paramagnetic Rim Lesions Highly Specific in MS Diagnosis
The presence of paramagnetic rim lesions (PRLs) on MRI was highly specific for multiple sclerosis (MS) in people suspected to have the disease, a prospective multicenter study showed. Based on 2017 McDonald criteria for MS diagnosis, the presence of one or more PRLs showed 88% specificity (95% CI 79-98%), 80% sensitivity (95% CI 68-91%), and […]